Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Globus Medical Reports Strong Q2 2026 Growth Driven by Spine Momentum:Globus Medical recorded $789.6M in quarterly net sales (+5.9% YoY), highlighted by 7% growth in US Spine and 14% growth in International Spine, signaling sustained surgeon adoption of its musculoskeletal and robotic platforms.
• Q2 MedTech Financial Shift & Revenue Realignments: Major orthopaedic players reported mixed Q2 2026 performance; while Zimmer Biomet and Orthofix demonstrated solid operational momentum, Smith+Nephew lowered full-year sales growth guidance from 6% to 4% following a 7.2% decline in knee implant revenues.
• Next-Gen Surgical Robotics & Implant Clearances: FDA clearances continue to expand robotic and smart surgical solutions, including LEM Surgical's Dynamis humanoid spine robot and Stryker's Triathlon Gold femoral components.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

LEM Surgical — FDA 510(k) Clearance Granted for Dynamis® Next-Gen Humanoid Robotic Surgical System

• Summary: LEM Surgical announced an expanded FDA 510(k) clearance for its Dynamis® robotic surgical platform, adding individual vertebra tracking, bi-manual stabilization workflows, and cervical spine capabilities. The humanoid 3-arm platform utilizes two guidance arms and one optical tracking arm to continuously track multi-segment spinal kinematics during surgical execution.
• Key Details:
  • Device/System Name: Dynamis® Robotic Surgical System
  • Status: FDA 510(k) Cleared
  • Clinical Significance: Enables real-time, independent multi-vertebra tracking and segment stabilization, lowering radiation exposure and improving alignment accuracy during spinal fixation.
• Original Source:LEM Surgical Press Release

Joint Reconstruction (Hip, Knee, Shoulder)

Zimmer Biomet — Reports Q2 2026 Financial Results & Expands ROSA® Robotics Ecosystem

• Summary: Zimmer Biomet reported solid Q2 2026 financial performance across its joint reconstruction portfolio. The company highlighted accelerating global adoption of its ROSA® Surgical Robotics suite, including the ongoing commercial rollout of ROSA® Shoulder and upcoming development milestones for posterior hip navigation.
• Key Details:
  • Device/System Name: ROSA® Robotics & Persona IQ® Smart Knee Platform
  • Status: Commercial Operations / Q2 Earnings Release
  • Clinical Significance: Drives surgical precision and standardized implant placement across total joint arthroplasty while capturing actionable intraoperative kinematics.
• Original Source:Zimmer Biomet Q2 2026 Press Release

Smith+Nephew — Reports Q2 2026 Financial Results & Adjusts Full-Year Outlook

• Summary: Smith+Nephew published its Q2 2026 financial update, generating $1.6B in revenue (+1.6% underlying growth). A 7.2% decline in knee implant sales prompted management to adjust full-year revenue growth expectations to 4% (down from 6%).
• Key Details:
  • Device/System Name: CORI® Surgical System & Hip/Knee Arthroplasty Portfolio
  • Status: Commercial Operations / Q2 Earnings Release
  • Clinical Significance: Highlights shifting market dynamics and competitive pressures in total joint replacement, emphasizing the importance of differentiated digital enabling technologies in ASC settings.
• Original Source:Smith+Nephew Q2 2026 Earnings Analysis

Maxx Orthopedics — Expands Libertas® Hip & Joint Replacement System Portfolio

• Summary: Maxx Orthopedics announced commercial expansion for its Libertas® Bipolar Hip System following recent regulatory approvals. Designed to address femoral head construct versatility in hemiarthroplasty and primary total hip replacement, the system provides modular sizing and optimized head-to-stem stability.
• Key Details:
  • Device/System Name: Libertas® Bipolar Hip System
  • Status: Commercial Expansion / FDA 510(k) Cleared
  • Clinical Significance: Offers optimized biomechanical stability and wear characteristics, reducing dislocations and operative time in hip fracture and reconstruction cases.
• Original Source:Maxx Orthopedics Press Release

Spine & Orthobiologics

Globus Medical — Reports Q2 2026 Net Sales of $789.6M (+5.9% YoY) Driven by US and International Spine Gains

• Summary: Globus Medical announced strong Q2 2026 financial results with net sales reaching $789.6 million, an increase of 5.9% year-over-year. Growth was led by US Spine (+7%) and International Spine (+14% as-reported), demonstrating market share gains across spinal fixation, expandable interbody cages, and ExcelsiusGPS® navigation robotics following the integration of Nevro.
• Key Details:
  • Device/System Name: ExcelsiusGPS® Robotic Navigation & Spinal Fixation Portfolio
  • Status: Commercial Operations / Q2 Earnings Release
  • Clinical Significance: Provides evidence of growing clinical adoption of robotic navigation and expandable interbody solutions in complex spinal fusion procedures.
• Original Source:Globus Medical Press Release

Orthofix Medical — Announces Q2 2026 Operational Results & Expansion in Bone Growth Therapies

• Summary: Orthofix Medical reported Q2 2026 financial results showcasing revenue progress across its core spine fixation, bone growth stimulation, and orthobiologics business lines.
• Key Details:
  • Device/System Name: Orthofix Spine Fixation & Bone Growth Therapy Portfolio
  • Status: Commercial Operations / Q2 Earnings Release
  • Clinical Significance: Supports non-invasive bone healing protocols and structural graft integration in high-risk fusion candidates.
• Original Source:Orthofix Investor Relations News

Corporate, M&A & Regulatory

Stryker — Declares $0.88 Quarterly Dividend

• Summary: Stryker Corporation's Board of Directors declared a quarterly dividend of $0.88 per share, payable October 30, 2026, representing a 4.8% increase over the prior year.
• Key Details:
  • Device/System Name: Corporate Dividend Announcement
  • Status: Board Approved
  • Clinical Significance: Reflects steady capital allocation and re-investment capacity into orthopaedic R&D and digital surgery platforms.
• Original Source:Stryker Investor Relations Release

Enovis — Reports Q2 2026 Earnings & Expands Technology Offerings

• Summary: Enovis Corporation announced its Q2 2026 financial results, reflecting growth across its reconstructive and prevention & recovery segments.
• Key Details:
  • Device/System Name: Enovis Reconstructive & ASC Portfolio
  • Status: Commercial Operations / Q2 Earnings Release
  • Clinical Significance: Broadens reconstructive option access and patient recovery pathways for outpatient joint and foot/ankle procedures.
• Original Source:Enovis Press Releases

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)